Immutep touts mid-stage data for LAG-3 drug in first-line NSCLC, finalizing plans for PhIII test: #ESMO23
MADRID — Immutep unveiled additional data at ESMO from a Phase II trial studying a LAG-3 drug designed to help certain non-small cell lung cancer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.